Incorrect description of mode of excretion of linagliptin
Hans-Juergen Woerle, Sanjay PatelBoehringer Ingelheim GmbH, GermanyDear Dr Zhou,Boehringer Ingelheim, owner of the investigational drug linagliptin, would like to point out that in the recent review paper by Cox and colleagues,1 titled “Dipeptidyl peptidase-4 inhibitors in the manageme...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-06-01
|
| Series: | Drug, Healthcare and Patient Safety |
| Online Access: | http://www.dovepress.com/incorrect-description-of-mode-of-excretion-of-linagliptin-a4547 |